Literature DB >> 12077098

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

I J Hickman1, A D Clouston, G A Macdonald, D M Purdie, J B Prins, S Ash, J R Jonsson, E E Powell.   

Abstract

BACKGROUND: Steatosis occurs in more than 50% of patients with chronic hepatitis C and is associated with increased hepatic fibrosis. In many of these patients the pathogenesis of steatosis appears to be the same as for patients with non-alcoholic fatty liver disease-that is, related to visceral adiposity and obesity.
METHODS: The effect of a three month weight reduction programme on liver biochemistry and metabolic parameters was examined in 19 subjects with steatosis and chronic hepatitis C. Paired liver biopsies were performed in 10 subjects, prior to and 3-6 months following the intervention, to determine the effect of weight loss on liver histology.
RESULTS: There was a mean weight loss of 5.9 (3.2) kg and a mean reduction in waist circumference of 9.0 (5.0) cm. In 16 of the 19 patients, serum alanine aminotransferase levels fell progressively with weight loss. Mean fasting insulin fell from 16 (7) to 11 (4) mmol/l (p<0.002). Nine of 10 patients with paired liver biopsies had a reduction in steatosis irrespective of viral genotype. In these subjects the median modified Knodell fibrosis score decreased from 3 to 1 (p=0.04) and activated stellate cells significantly decreased (p<0.004).
CONCLUSIONS: Weight loss in patients with chronic hepatitis C may be associated with a reduction in steatosis and abnormal liver enzymes and an improvement in fibrosis, despite the persistence of the virus. Weight reduction may provide an important adjunct treatment strategy for patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077098      PMCID: PMC1773265          DOI: 10.1136/gut.51.1.89

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  Diet modulates Th-1 and Th-2 cytokine production in the peripheral blood of lupus-prone mice.

Authors:  C A Jolly; G Fernandes
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.317

2.  Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients.

Authors:  L E Adinolfi; R Utili; G Ruggiero
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors.

Authors:  R Issa; E Williams; N Trim; T Kendall; M J Arthur; J Reichen; R C Benyon; J P Iredale
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production.

Authors:  D Arsenijevic; H Onuma; C Pecqueur; S Raimbault; B S Manning; B Miroux; E Couplan; M C Alves-Guerra; M Goubern; R Surwit; F Bouillaud; D Richard; S Collins; D Ricquier
Journal:  Nat Genet       Date:  2000-12       Impact factor: 38.330

Review 5.  Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

Authors:  F H Luyckx; P J Lefebvre; A J Scheen
Journal:  Diabetes Metab       Date:  2000-04       Impact factor: 6.041

6.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

Authors:  L Rubbia-Brandt; R Quadri; K Abid; E Giostra; P J Malé; G Mentha; L Spahr; J P Zarski; B Borisch; A Hadengue; F Negro
Journal:  J Hepatol       Date:  2000-07       Impact factor: 25.083

7.  Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.

Authors:  I Shimomura; Y Bashmakov; S Ikemoto; J D Horton; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

8.  The relationship between body mass index and waist circumference: implications for estimates of the population prevalence of overweight.

Authors:  M L Booth; C Hunter; C J Gore; A Bauman; N Owen
Journal:  Int J Obes Relat Metab Disord       Date:  2000-08

9.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.

Authors:  L E Adinolfi; M Gambardella; A Andreana; M F Tripodi ; R Utili; G Ruggiero
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

10.  Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation.

Authors:  A D Clouston; J R Jonsson; D M Purdie; G A Macdonald; N Pandeya; C Shorthouse; E E Powell
Journal:  J Hepatol       Date:  2001-02       Impact factor: 25.083

View more
  50 in total

1.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

2.  Weighty issues in hepatitis C.

Authors:  J Heathcote
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  When to treat patients with chronic hepatitis C.

Authors:  Jenny Heathcote; Alnoor Ramji
Journal:  Curr Gastroenterol Rep       Date:  2004-08

4.  Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done?

Authors:  Donald M Jensen
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

5.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

6.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 7.  Inflammation and conjugated linoleic acid: mechanisms of action and implications for human health.

Authors:  M A Zulet; A Marti; M D Parra; J A Martínez
Journal:  J Physiol Biochem       Date:  2005-09       Impact factor: 4.158

8.  Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.

Authors:  Yang Cheng; Sébastien Dharancy; Mathilde Malapel; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

9.  Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome.

Authors:  M Vázquez-Vandyck; S Roman; J L Vázquez; L Huacuja; G Khalsa; R Troyo-Sanromán; A Panduro
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

10.  Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Authors:  Anna S Lok; James E Everhart; Raymond T Chung; Hae-Young Kim; Gregory T Everson; John C Hoefs; Joel K Greenson; Richard K Sterling; Karen L Lindsay; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany; Chihiro Morishima
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.